Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06334159

Guided Bone Regeneration Using Fixed vs Non-Fixed Resorbable Collagen Membranes

The aim of this clinical trial is to compare the horizontal bone gain when grafting a bone substitute with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring Guided Bone Regeneration (GBR) to facilitate implant placement at 6 months.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Georgios Markantonatos

Barcelona, Sant Cugat Del Vallès, 08195, Spain

Location status: Recruiting

Location contact

Cristina Vallès, DDS, MS, PhD

PRINCIPAL_INVESTIGATOR

Georgios Markantonatos, DDS

CONTACT

[email protected]

+34666022568

About this study

The aim of this clinical trial is to compare the horizontal bone gain when grafting a mixture of xenograft and allograft (50/50) with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring Guided Bone Regeneration (GBR) to facilitate implant placement at 6 months.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women over 18 years old or older
  • Patients requiring Guided Bone Regeneration due to insufficient ridge width(≤5mm) to place dental implants, with sufficient vertical ridge height (≥9mm) from vital anatomical structures (the inferior alveolar nerve in the Mandible, or the sinus in the Maxilla)
  • One or more teeth missing in posterior zone (Premolars, and Molars)
  • Absence of active Periodontal disease
  • Good level of oral hygiene (Plaque index <25%)
  • Absence of systemic diseases that could influence the outcome of the therapy (Uncontrolled diabetes, osteoporosis, bisphosphonate medications)
  • Non smokers or light smokers (<10 cigarettes per day)
  • Informed consent signed

Exclusion criteria

  • Patients with sufficient ridge width (>5 mm) and height (≥9mm) from vital anatomical structure) requiring no GBR to place dental implants
  • Patients with severe horizontal and vertical defects requiring other surgical techniques.
  • Long-term non-steroidal anti-inflammatory drug therapy (3months).
  • Lactating females or currently pregnant women.
  • Severe cognitive or psychiatric disorders.
  • Unwillingness to return for follow-up examination.

Treatment and study plan

Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane

Procedure

Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).

Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane

Procedure

Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).

Primary outcomes

  1. Horizontal Bone Gain

    Time frame: T3: 6 months after the Horizontal GBR

    To compare the horizontal bone gain when grafting a mixture of xenograft and allograft (50/50) with non-fixed resorbable collagen membranes (control group) versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring GBR to facilitate implant placement at 6 months.

    Along the 6 months, 3 Cone Beam Computed Tomography scans (CBCT) will be needed. At baseline (T1), the first CBCT will be taken before performing any surgical procedure to measure the initial width of the ridge. Immediately after the GBR (T2), a second CBCT scan will be taken, which will be useful to measure new ridge width in each group. Finally, at 6 month follow-up a third CBCT scan will be taken (T3) in order to assess the difference with T1 regarding amount of bone gain horizontally, and with T2 regarding horizontal dimensional stability of the grafted bone in each of the 2 groups.

  2. Bone Width Gain

    Time frame: T3: 6 months after the Horizontal GBR

    To compare the bone width gain between the test group and control group, 6 months after the horizontal GBR.

    A caliper will be used in order to evaluate and compare the bone width gain at T1, T2, and T3 between the Test and Control Groups. These measurements are performed intra-operatively before the Horizontal GBR (T1), immediately after (T2), and at 6 months (T3) at the time of implant placement. Measurements will be performed at 1cm, 3cm, and 5cm apical from the bone crest at the regenerated area.

Secondary outcomes

  1. Horizontal Dimensional Stability

    Time frame: T3: 6 months after the Horizontal GBR

    To compare the horizontal dimensional stability of the augmented ridges between the test group and control group after 6 months.

    After the surgical procedure, a CBCT scan (T2) will be completed and the bone width will be assessed and compared with the bone width at 6 months postoperatively when a new CBCT scan (T3) will be completed before implant placement.

  2. Post-surgical complications

    Time frame: T2-T3: From the surgery to 6 months

    To compare the post-surgical complications that may occur between the test group and control group throughout the period of healing and during the following 6 months. The complications will be evaluated using the Healing Complications Classification, as suggested by Fontana et al. 2011. The healing post-surgical complications are divided into four classes, according to the presence and extent of exposure, as well as the presence of a purulent exudate:

    • Class I: membrane exposure <3mm, no purulent exudate
    • Class II: membrane exposure ≥3mm, no purulent exudate
    • Class III: membrane exposure with purulent exudate
    • Class IV: abscess, without membrane exposure
  3. Patient's satisfaction

    Time frame: At 2-weeks follow up after the surgical procedure

    To compare patient's satisfaction regarding the post-operative pain and compare it between the test group and control group throughout the period of healing and during the following 6 months, through the use of a Visual Analogue Scale (VAS). It is a 10cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patients will be asked to mark their average experience of discomfort and pain. The scores of the VAS will be obtained by measuring the distance in centimeters (0 to 10).

  4. Histologic examination of the augmented bone at 6 months

    Time frame: At time of implant placement

    To examine type of cells present after 6 months of procedure by performing histological examination to the sample harvested from the site with the use of an implant trephine drill. The histologic evaluation will be performed in order to evaluate the type of cells present at the site of augmentation

Study contacts

Contact information is provided by the study sponsor or research team.

Georgios Markantonatos, DDS

CONTACT

[email protected]

+34666022568

Sponsors and collaborators

Lead sponsor

Universitat Internacional de Catalunya

Other

Registry information

Official study title

Guided Bone Regeneration Using Fixed vs Non-Fixed Resorbable Collagen Membranes: A Randomized Controlled Clinical Trial

Important dates

Study start
2020
Primary completion
2025
Study completion
2027
First posted
Mar 27, 2024
Registry last updated
Mar 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.